Fig. 1 | Scientific Reports

Fig. 1

From: Real-world study of first-line immunotherapy combined with chemoradiotherapy in esophageal squamous cell carcinoma

Fig. 1

Analysis of the Impact of absolute lymphocyte count (ALC) Levels at different time periods on prognosis; A Baseline ALC for overall survival; B Baseline ALC for progression free survival; C Mid-treatment ALC for overall survival; D Mid-treatment ALC for progression free survival; E Post-treatment ALC for overall survival; F Post-treatment ALC for progression free survival.

Back to article page